Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene (This gene does not contain this module)
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: GNLY

Summary for GNLY

Gene information	Gene symbol	GNLY
	Ensembl ID	ENSG00000115523
	Entrez ID	10578
	Gene name	granulysin
	Synonyms	D2S69E\|LAG-2\|LAG2\|NKG5\|TLA519
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: GNLY

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	-0.543637	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.559824	1.50e-33
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	-0.722619	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	-0.589024	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	-0.343726	9.63e-24
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	-0.612291	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	CD8+ T cells	0.434598	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	NK cells	0.452372	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	2.66365	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	NK cells	0.785293	9.21e-06
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	CD8+ T cells	-0.295086	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.454233	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	post	CD8+ T cells	-0.352132	9.67e-44
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	0.337361	7.77e-23
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	2.45308	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	NK cells	-1.03372	2.16e-10
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	-0.475429	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	NK cells	0.583846	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD4+ T cells	-0.536104	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	-0.468163	3.97e-12
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	0.753458	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	0.657441	7.33e-23
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	B cells	0.874357	1.97e-02
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	cDCs	0.663465	3.30e-02
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	0.5196	8.07e-33
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-1.76343	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD4+ T cells	-0.747583	2.68e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-1.05956	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	0.499992	7.86e-11
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	1.79893	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	1.61378	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	1.66606	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	-0.987903	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	-0.504558	7.79e-24
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	B cells	-0.455359	2.13e-07
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	-0.460545	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD8+ T cells	-0.641481	1.60e-40

Top

Expression of GNLY in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to GNLY

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating GNLY

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Top

Motifs and transcription factors (TFs) regulating GNLY

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
GNLY	taipale_tf_pairs__TEAD4_ERG_RSCGGAAATRCC_CAP_repr	ERG; TEAD4 (directAnnotation).
GNLY	taipale_tf_pairs__TEAD4_ERG_RSCGGAAATRCC_CAP	ERG; TEAD4 (directAnnotation).
GNLY	tfdimers__MD00349	GABPA; YY2 (directAnnotation).
GNLY	transfac_pro__M06257	ZNF616 (directAnnotation).
GNLY	transfac_pro__M05354	ZNF800 (inferredBy_Orthology).
GNLY	tfdimers__MD00079	E2F1; FOXM1 (directAnnotation).
GNLY	transfac_pro__M06642	ZSCAN10 (directAnnotation).
GNLY	transfac_pro__M06783	ZNF443 (directAnnotation).
GNLY	hdpi__FOSL1	FOSL1 (directAnnotation).
GNLY	hocomoco__FOXJ3_HUMAN.H11MO.1.B	FOXJ3 (directAnnotation).
GNLY	metacluster_134.6	FOXF1; FOXG1; ZNF74 (directAnnotation). FOXG1 (inferredBy_Orthology).
GNLY	metacluster_188.3	FOXJ3; FOXJ3; FOXP1; FOXP1 (directAnnotation). FOXO1; FOXO4; FOXP1 (inferredBy_Orthology).
GNLY	tfdimers__MD00376	HOXA13; KLF4 (directAnnotation).
GNLY	tfdimers__MD00218	ATF1; ATF2; ATF3; ATF4; ATF7; CREB1; CREM; ELF1 (directAnnotation).
GNLY	taipale_tf_pairs__MYBL1_TBX21_AGGTGTGNCSGTTR_CAP_repr	MYBL1; TBX21 (directAnnotation).
GNLY	metacluster_53.2	ZNF8 (directAnnotation).
GNLY	transfac_pro__M05744	ZXDC (directAnnotation).
GNLY	transfac_pro__M07066	STAT6 (directAnnotation).
GNLY	metacluster_56.4	HSF1; HSF2; HSF2; HSF4 (directAnnotation).
GNLY	metacluster_52.10	GTF3C2; ZNF436 (directAnnotation).
GNLY	transfac_pro__M05782	ZNF324B (directAnnotation).
GNLY	taipale_tf_pairs__ELK1_TBX21_TNRCACCGGAAGNN_CAP	ELK1; TBX21 (directAnnotation).
GNLY	taipale_tf_pairs__HOXB2_NHLH1_NYMATTANNNNNNCAGCTGNN_CAP_repr	HOXB2; NHLH1 (directAnnotation).
GNLY	yetfasco__TBP-TFIIB_1329	GTF2B; TBPL2 (inferredBy_Orthology).
GNLY	transfac_pro__M04855	IRF4 (directAnnotation).
GNLY	transfac_pro__M05901	ZNF561 (directAnnotation).
GNLY	transfac_pro__M06231	ZNF273 (directAnnotation).
GNLY	tfdimers__MD00056	EP300; ZEB1 (directAnnotation).
GNLY	metacluster_160.19	ZNF526 (directAnnotation). ZNF526 (inferredBy_Orthology).
GNLY	transfac_pro__M05846	ZNF689 (directAnnotation).
GNLY	metacluster_142.1	ZNF248 (directAnnotation). POU3F1; POU3F2 (inferredBy_Orthology).
GNLY	transfac_pro__M06896	ZFP3 (inferredBy_Orthology).
GNLY	transfac_pro__M06724	ZNF331 (directAnnotation).
GNLY	transfac_pro__M06317	ZNF829 (directAnnotation).
GNLY	transfac_pro__M05904	ZNF564 (directAnnotation).
GNLY	transfac_pro__M06220	ZNF155 (directAnnotation).
GNLY	transfac_pro__M06183	ZNF132 (directAnnotation).
GNLY	transfac_pro__M04848	TAF1 (directAnnotation).
GNLY	jaspar__MA0033.2	FOXL1 (directAnnotation).
GNLY	transfac_pro__M06869	ZNF600 (directAnnotation).
GNLY	metacluster_29.6	ZNF436 (directAnnotation).
GNLY	transfac_pro__M02085	BCL6 (directAnnotation).
GNLY	metacluster_93.4	BCL6B (directAnnotation).
GNLY	transfac_pro__M05913	ZIM3 (directAnnotation).
GNLY	metacluster_27.1	FOXP3; FOXP3 (directAnnotation).
GNLY	transfac_pro__M08190	AR (directAnnotation).
GNLY	transfac_pro__M06339	ZNF425 (directAnnotation).
GNLY	taipale__Esrra_DBD_TTCAAGGTCAN_repr	ESRRA (inferredBy_Orthology).
GNLY	transfac_pro__M05540	ZBTB34 (directAnnotation).
GNLY	transfac_pro__M06588	ZNF845 (directAnnotation).

Page: 1 2 3 4

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
GNLY	"3-(N-morpholino)propanesulfonic acid"	DB03434	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."